A MoCRA Timeline for a Brand Launching in 2026

If you're planning a 2026 launch, the compliance work needs to sit on your calendar next to the fun parts, packaging design, influencer samples, launch week promo, not get bolted on the week before you ship. Here's how I'd actually sequence it for a brand aiming to launch this year.

Start with the MoCRA basics you're building around

MoCRA, the Modernization of Cosmetics Regulation Act from 2022, requires facility registration and product listing with the FDA, a named responsible person, safety substantiation for your products, and adverse event recordkeeping. Some small businesses are exempt from the registration and listing pieces specifically, so the very first thing on your timeline should be figuring out honestly whether that exemption applies to you, rather than assuming either that it definitely does or definitely doesn't.

One more foundational check before you build the rest of the plan: if your product functions as a sunscreen, or otherwise makes drug-type claims like anti-acne or antiperspirant, it's regulated as an OTC drug, not a cosmetic, and MoCRA's cosmetic-specific pathway isn't the right framework for it at all. Get this classification right before you build any further timeline around it.

Twelve months out: formulation and safety groundwork

This is the stage where safety substantiation should start, not the month before launch. Substantiation means having adequate support that your product is safe under labeled or customary use conditions, and the depth of that support should scale with the product. A simple anhydrous lip balm with a handful of well-known ingredients needs less extensive substantiation than a leave-on serum with actives and a longer ingredient list. Start assembling whatever safety data, ingredient safety information, and any testing you're commissioning during this window, because rushing substantiation at the end is how gaps get missed.

Nine to six months out: responsible person and facility questions

Decide who your named responsible person is. This isn't a symbolic title, it's the party accountable for the safety substantiation and adverse event obligations under MoCRA, so it needs to be a real, considered decision, not an afterthought filled in on a form. If you're manufacturing in-house, your facility registration work belongs in this window too. If you're using a contract manufacturer, confirm directly who handles facility registration on their end and don't assume it's automatically covered.

Six to three months out: product listing and ingredient documentation

Product listing with the FDA is where your formula, as a finished product, gets documented on the regulatory side. This is also the point to finalize your actual ingredient deck: full INCI names, accurate concentrations, and a clear picture of anything hiding inside a supplier blend, since fragrance and functional blends often expand into several components once you get the real breakdown from a supplier.

The fragrance allergen wrinkle, even for a US launch

If your brand has any ambition to sell into Canada alongside the US, and a lot of small brands do within their first year or two, keep Canada's fragrance allergen disclosure dates on your radar even while you're primarily focused on MoCRA. Health Canada's List 1 fragrance allergens become mandatory on the CNF and label on April 12, 2026, with List 2 following August 1, 2026. Building your fragrance allergen documentation once, at launch, rather than retrofitting it later for a second market, saves real time.

Three months out to launch: labeling, recordkeeping systems, and final checks

Set up your adverse event recordkeeping system before you have your first customer, not after your first complaint. MoCRA's recordkeeping obligation isn't something you can backfill convincingly once an issue has already occurred. Finalize label copy against your actual product listing and safety substantiation, and do a last pass confirming nothing in your marketing claims has quietly drifted from cosmetic territory into implied drug claims.

A simplified timeline table

Timeframe before launch	Focus
12 months	Confirm cosmetic vs. drug classification; begin safety substantiation
9 to 6 months	Name responsible person; handle facility registration (in-house or confirm with contract manufacturer)
6 to 3 months	Complete FDA product listing; finalize INCI and concentration documentation
3 months to launch	Set up adverse event recordkeeping; finalize labels; confirm claims stay cosmetic, not drug
Ongoing after launch	Maintain adverse event records; revisit listing if formula changes

The honest note about small business exemptions

Don't let "some small businesses are exempt" become an excuse to skip the analysis. Whether you qualify depends on specifics of your business that can change as you grow, and assuming exemption without checking is a worse position than confirming it early and revisiting the question as your revenue and production scale up.

Cosmetic Comply's Canada workflow is live today for makers who want that side handled now, and US MoCRA-aligned tooling is on the way, so if you're building a 2026 launch that's likely to cross into Canada at some point, it's worth setting up your ingredient documentation once in a format that can carry over rather than redoing it market by market.